SCHEMBL1188965

SCHEMBL1188965

C[C@H]1CN(C)CCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8207333 1.00
SCHEMBL1189608 1.00
SCHEMBL82072 1.00
Hydrochloric Acid SCHEMBL17272031 0.97
Hydrochloric Acid SCHEMBL1188804 0.97 BIRC2 (0.36)
Hydrochloric Acid SCHEMBL22576775 0.97
Hydrochloric Acid SCHEMBL1191003 0.97 BIRC2 (0.36)
Hydrochloric Acid SCHEMBL1191130 0.97 BIRC2 (0.36)
Piperazine SCHEMBL28119784 0.93 BIRC2 (0.34)
Piperazine SCHEMBL28304131 0.91 BIRC2 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
WO-2026102212-A1 MACROCYCLIC MCL-1 INHIBITORS VANDERBILT UNIVERSITY (US) 2026-05-15 WO disclosed
EP-4741392-A1 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF Shenzhen TargetRx Co., Ltd. (CN) 2026-05-13 EP disclosed
CN-122029158-A EGFR inhibitors 缆图药品公司 2026-05-12 CN disclosed
US-20260124214-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2026-05-07 US disclosed
CN-121873002-A Synthesis method and application of (3S) -1, 3-dimethylpiperazine-2-one 上海毕得医药科技股份有限公司 2026-04-17 CN disclosed
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 EP disclosed
EP-4720678-A1 SURVIVIN AS A BIOMARKER FOR PREDICTING THE RESPONSIVENESS OF CANCER TREATMENT Boehringer Ingelheim International GmbH (DE) 2026-04-08 EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 US disclosed
US-12545670-B2 Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2026-02-10 US disclosed
WO-2009100167-A1 DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS GLAXO GROUP LIMITED (GB) 2009-08-13 WO disclosed
WO-2009061879-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-05-14 WO disclosed
US-7531554-B2 Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid JAPAN TOBACCO INC. (JP) 2009-05-12 US disclosed
US-7531554-B2 Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid JAPAN TOBACCO INC. (JP) 2009-05-12 US disclosed
US-7414057-B2 Piperazine urea derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2008-08-19 US disclosed
WO-2008079284-A1 PROCESS FOR PREPARING CCR-5 RECEPTOR ANTAGONISTS UTILIZING 4-SUBSTITUTED 1-CYCLOPROPANE-SULFONYL-PIPERIDINYL COMPOUNDS SCHERING CORPORATION (US) 2008-07-03 WO disclosed
WO-2007055942-A2 SUBSTITUTED NICOTINAMIDE COMPOUNDS MERCK & CO., INC. (US) 2007-05-18 WO disclosed
WO-2006046135-A2 PYRAZOLO[4,3-D] PYRIMIDINE DERIVATIVES USEFUL AS PDE-5 INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-05-04 WO disclosed
EP-1204654-A1 BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS ELI LILLY AND COMPANY (US) 2002-05-15 EP disclosed
WO-2001009111-A1 BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS ELI LILLY AND COMPANY (US) 2001-02-08 WO disclosed